FDA scientists opposed plan to ease access to unproven peptide drugs

Most FDA scientific staff opposed a plan to ease access to unproven peptide drugs favoured by US Health Secretary Robert F Kennedy Jr, according to six people familiar with it. The HHS policy tells the FDA not to act against specialty pharmacies selling a handful of injectable wellness peptides, including BPC-157, TB-500 and KPV, which are promoted for muscle-building and healing.